skip to Main Content

Cardiovascular Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes

Cardiovascular (CV) events are the most common cause of death among adults with type 2 diabetes. While the benefits and safety of commonly used blood pressure and cholesterol medications are well established, much less is known about the CV benefits and safety of many commonly used therapies to control glucose. In this project, we carefully assess the impact of specific glucose-lowering strategies on CV events (myocardial infarction and stroke) and on mortality, in order to identify whether some glucose-lowering strategies confer more CV benefit or risks than others. To address this important clinical and public health concern, we will test several specific comparative effectiveness hypotheses, in an electronic medical record-linked Health Care Systems Research Network-based registry of over 650,000 adults with diabetes receiving care in 4 large U.S. health care systems.

Investigator: Schmittdiel, Julie

Funder: National Heart, Lung, and Blood Institute

Explore all studies and publications

Back To Top